FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Relevant for: previvors, In portal: Breast Cancer
Relevance: Medium-High
Research Timeline: Post Approval
Study : FDA report claims women with breast implants may be at risk for rare cancer
Most relevant for: Women who had or are consideration breast reconstruction with implants
THIS INFORMATION HAS BEEN UPDATED. The FDA issued an update in March, 2018 about Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). This was covered in a more recent XRAY review. On 07/25/19, the FDA announced a recall of Allergan BIOCELL textured implants and expanders, due to their association with BIA-ALCL. This was also covered in a more recent XRAY review.
Recent headlines highlighted an FDA report stating that patients with breast implants may be at increased risk for a rare type of non-Hodgkin lymphoma. What is the scientific evidence behind this claim? (4/21/17)
Read More
Relevance: Medium-High
Strength of Science: Medium
Study : Women with breast cancer symptoms but no lump may wait longer to seek medical care
Relevance: Medium-High
Strength of Science: Medium
Most relevant for: People with breast cancer symptoms
Some patients take longer than others before getting a potential breast cancer checked by their health care provider. Believing that women who have breast cancer symptoms but have no lump may wait longer, researchers in this study used data from women who were diagnosed with breast cancer in 2009 and 2010 to identify possible explanations. (1/18/17)
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Study : High vitamin D levels at breast cancer diagnosis may be associated with a better prognosis
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: Women at average risk for breast cancer and newly diagnosed women
Vitamin D is most known for its role in maintaining bone health but vitamin D has additional roles in keeping us healthy. In this study, researchers found that breast cancer patients who had the highest amounts of vitamin D in their blood (slightly over the recommended levels) had better health outcomes, including overall survival, than women with lower amounts of vitamin D. This finding adds to the growing evidence for the role of vitamin D in cancer, but it does not change how breast cancer is prevented or treated. (1/10/17)
Read More
Relevance: Medium
Strength of Science: Medium-Low
Study : Angelina Jolie spoke out on BRCA testing: Did genetic testing increase?
Most relevant for: People interested in genetic testing for an inherited mutation
Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)
Read More
Relevance: Medium-High
Quality of Writing: Medium-High
Article : After mastectomy: reconstruct or not?
Most relevant for: Woman who are facing mastectomy
Today, more women know they can have breast reconstruction after removing their breasts for cancer treatment or risk reduction. But what about choosing not to undergo reconstruction? Roni Caryn Rabin writes about the experiences of women who decide against reconstruction in her New York Times piece “‘Going Flat’ After Breast Cancer.” (12/14/16)
Read More
Relevance: Medium
Quality of Writing: Medium-Low
Personal Story : Why one woman passed on genetic testing
Most relevant for: People considering genetic testing and people who are Ashkenazi Jewish
What are reasons to get or not get genetic testing? Cynthia Graber gives her thoughts on the matter in her Wired opinion piece, "Why I Won't Get the Genetic Test for Breast Cancer." (11/15/16)
Read More
Relevance: Medium
Strength of Science: Medium-High
Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women
Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries
Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study
As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)
Read More
Relevance: Medium-Low
Quality of Writing: Medium-Low
Personal Story : Dogs: Companions, hunters, and cancer detectors?
Relevance: Medium-Low
Quality of Writing: Medium-Low
Most relevant for:
In August 2016, many news outlets published stories about how actress Shannen Doherty’s dog was able to sniff out her cancer before she was diagnosed. Is there scientific validity to that claim? (9/616)
Read More
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
Study : Early research on a drug to prevent breast cancer
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
Most relevant for: Women with a BRCA1 mutation
Many researchers are interested in non-surgical options to reduce the higher-than-average risk of developing breast cancer in BRCA mutation carriers. This research study identified a type of drug, called a “RANK ligand inhibitor,” that may prevent breast cancer. Among mice that were genetically engineered to have no BRCA1 genes, those that were given the drug developed tumors less frequently than those that did not. While this is an exciting early study for BRCA mutation carriers, more work and human clinical trials need to be done before this can be used as a prevention therapy in humans. (7/12/16)
Update added 11/24/19: The RANK ligand inhibitor, denosumab is currently being studied as a possible breast and ovarian cancer preventive agent in human clinical trials.
Read More